Browsing by Author "Kawaguchi T."

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    ItemMetadata only
    Advanced radiographic osteoarthritis is associated with 5-year coronal varus progression in alignment and bone morphology in a community-based cohort of older adults
    (2026-01-01) Morita Y.; Nishitani K.; Kawaguchi T.; Sinthunyathum P.; Morita Y.; Nakamura S.; Kuriyama S.; Ito H.; Matsuda F.; Matsuda S.; Morita Y.; Mahidol University
    Purpose: This study aimed to quantify 5-year changes in coronal lower limb alignment and evaluate their associations with baseline osteoarthritis severity. Methods: In the Nagahama cohort, adults ≥60 years underwent weight-bearing knee radiographs at baseline and 5 years later. Alignment parameters included the anatomical lateral distal femoral angle (aLDFA), medial proximal tibial angle (MPTA), joint line convergence angle (JLCA) and femorotibial angle (FTA). Changes were tested using paired t tests, and associations were modelled using Gaussian generalized linear models adjusted for age, sex, body mass index and baseline Kellgren–Lawrence (K–L) grade. Group differences among K–L ≤ 1, 2 and ≥3 were tested by one-way analysis of variance with Tukey's Honestly Significant Difference, and within-group correlations were assessed using Pearson's coefficient. Results: A total of 2974 knees were analysed. Baseline K–L grades were: 0: 164 (5.5%), 1: 1975 (66.4%), 2: 694 (23.3%), 3: 135 (4.5%) and 4: 6 (0.2%). Over 5 years, FTA increased by 0.3° (p < 0.001). aLDFA also shifted 0.3° toward the varus (p < 0.001), whereas MPTA and JLCA remained stable. A higher baseline K–L grade was independently associated with varus progression, particularly when driven by decreased MPTA and increased JLCA. Consistent with the multivariable analysis, the K–L ≥ 3 group exhibited a significant MPTA decrease and a 2.6° varus shift in FTA. By contrast, K–L ≤ 2 groups showed no significant change in MPTA, whereas FTA showed a slight varus shift with a modest JLCA increase. In all subgroups, FTA change correlated with changes in aLDFA (r = 0.48–0.54), MPTA (r = −0.55 to −0.46) and JLCA (r = 0.21–0.48), with all p < 0.001. Conclusions: Coronal alignment shifted slightly toward varus over 5 years. In advanced OA, progression reflected a decreased MPTA and increased JLCA, with a modest aLDFA increase. Level of Evidence: Level I, prognostic studies—high-quality prospective cohort study.
  • No Thumbnail Available
    ItemMetadata only
    From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women
    (2024-05-01) Danpanichkul P.; Ng C.H.; Muthiah M.; Suparan K.; Tan D.J.H.; Duangsonk K.; Sukphutanan B.; Kongarin S.; Harinwan N.; Panpradist N.; Takahashi H.; Kawaguchi T.; Vichitkunakorn P.; Chaiyakunapruk N.; Nathisuwan S.; Huang D.; Arab J.P.; Noureddin M.; Mellinger J.L.; Wijarnpreecha K.; Danpanichkul P.; Mahidol University
    INTRODUCTION: The burden of alcohol-related complications is considerable, particularly alcohol-associated liver disease and alcohol use disorder (AUD). However, there are deficiencies in comprehensive epidemiological research focusing on these issues, especially among young women who display higher susceptibility to such complications compared with their male counterparts. We thus aimed to determine the global burden of these conditions in this vulnerable group. METHODS: Leveraging data from the Global Burden of Disease Study 2019, we analyzed the prevalence, mortality, and disability-adjusted life years of alcohol-associated cirrhosis (AC), liver cancer from alcohol, and AUD in young women. The findings were categorized by region, nation, and sociodemographic index. RESULTS: The highest age-standardized prevalence rates were observed in AUD (895.96 [95% uncertainty interval (UI) 722.6-1,103.58]), followed by AC (65.33 [95% UI 48.37-86.49]) and liver cancer from alcohol (0.13 [95% UI 0.09-0.19]) per 100,000 people. The highest age-standardized mortality rates were observed in AC (0.75 [95% UI 0.55-0.97]), followed by AUD (0.48 [95% UI 0.43-0.53]) and liver cancer from alcohol (0.06 [95% UI 0.04-0.09]). The highest burdens of AC and AUD were observed in Central Europe, whereas the high-income Asia Pacific had the highest burden of liver cancer from alcohol. DISCUSSION: Throughout the past decade, the trend of AUD varied among regions while the impact of alcohol-associated liver disease has increased, requiring urgent public health strategy to mitigate these complications, particularly in female patients in Europe and the Asia-Pacific region.
  • No Thumbnail Available
    ItemMetadata only
    The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
    (2025-04-01) Eslam M.; Fan J.G.; Yu M.L.; Wong V.W.S.; Cua I.H.; Liu C.J.; Tanwandee T.; Gani R.; Seto W.K.; Alam S.; Young D.Y.; Hamid S.; Zheng M.H.; Kawaguchi T.; Chan W.K.; Payawal D.; Tan S.S.; Goh G.B.b.; Strasser S.I.; Viet H.D.; Kao J.H.; Kim W.; Kim S.U.; Keating S.E.; Yilmaz Y.; Kamani L.; Wang C.C.; Fouad Y.; Abbas Z.; Treeprasertsuk S.; Thanapirom K.; Al Mahtab M.; Lkhagvaa U.; Baatarkhuu O.; Choudhury A.K.; Stedman C.A.M.; Chowdhury A.; Dokmeci A.K.; Wang F.S.; Lin H.C.; Huang J.F.; Howell J.; Jia J.; Alboraie M.; Roberts S.K.; Yoneda M.; Ghazinian H.; Mirijanyan A.; Nan Y.; Lesmana C.R.A.; Adams L.A.; Shiha G.; Kumar M.; Örmeci N.; Wei L.; Lau G.; Omata M.; Sarin S.K.; George J.; Eslam M.; Mahidol University
    Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for the Study of the Liver (APASL) has created clinical practice guidelines focused on MAFLD. The guidelines cover various aspects of the disease, such as its epidemiology, diagnosis, screening, assessment, and treatment. The guidelines aim to advance clinical practice, knowledge, and research on MAFLD, particularly in special groups. The guidelines are designed to advance clinical practice, to provide evidence-based recommendations to assist healthcare stakeholders in decision-making and to improve patient care and disease awareness. The guidelines take into account the burden of clinical management for the healthcare sector.